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Weighing the Evidence*Thomas J. Wang, MDSEE PAGE 2743O besity increases the risk for developingvarious cardiovascular conditions, includ-ing hypertension, ischemic heart disease,
and heart failure (HF) (1–3). Experimental studies
support detrimental effects of adiposity and insu-
lin resistance on the vasculature, cardiac function,
and remodeling (4,5). Thus, it is surprising that
obese and overweight patients with established
HF seem to have a better prognosis than lean pa-
tients. Initially made more than a decade ago (6),
this observation has been replicated in numerous
studies (7–11).
Can obesity really confer protection in patients
with HF? It helps to consider the potential
“noncausal” explanations for the reported associa-
tion between obesity and improved HF outcomes. The
“obesity paradox” is on the basis of ﬁndings from
observational studies, which have 3 principal threats
to validity (12). The ﬁrst is chance, as the need to set an
arbitrary p value threshold for declaring signiﬁcance
can lead to false positive ﬁndings. Nonetheless, the
large number of independent studies with concordant
ﬁndings—with a cumulative sample size of nearly
150,000 patients—makes chance an unlikely explana-
tion for the obesity paradox (6–11).
The second potential threat to validity is con-
founding. Unmeasured factors (confounders) sepa-
rately associated with exposure and outcome can
create the false impression that exposure and outcome
are causally related. In regards to the obesity paradox,
a potential confounder could be muscle wasting and
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poor prognosis, but the low BMI does not necessarily
contribute to the poor prognosis. Indeed, HF itself may
cause weight loss, an example of “reverse causality”
(13). The fact that the obesity paradox persists in
studies that exclude underweight patients does not
eliminate these threats to study validity, because a
catabolic state can exist in “normal-weight”
patients.The nicely-designed study by Khalid et al. (14) in
this issue of the Journal provides perhaps the best
evidence that the obesity paradox is not simply due to
cachexia in late-stage HF or reverse causality.
Leveraging a decade of longitudinal data from the
ARIC (Atherosclerosis Risk In Communities) study,
the investigators show that even pre-morbid obesity
is associated with improved HF survival. They stud-
ied 1,487 patients in ARIC with incident HF who
had BMI measured at least 6 months prior to diag-
nosis. The mean interval between BMI measurement
and HF diagnosis was 4 years, ensuring that the BMI
measurement was not confounded by HF-related
factors. After adjustment for clinical risk factors,
pre-morbid overweight and obesity were associated
with 23% and 25% reductions, respectively, in mor-
tality risk during 10-year follow-up. The study makes
excellent use of a well-characterized, epidemiological
cohort, and the ﬁndings represent a valuable contri-
bution to the ﬁeld.
However, several limitations in the study by Khalid
et al. (14) deserve consideration. These limitations
fall under the third category of threats to study val-
idity: bias. Bias can occur in participant selection for a
study sample (selection bias), data ascertainment
(information bias), or both. Bias introduces a sys-
tematic tendency to produce a certain ﬁnding, rather
than contributing random noise (which leads to the
ﬁrst problem, chance). How could bias create an
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2751artifactual association between obesity and improved
prognosis in HF? Obese patients may be more likely
to be diagnosed with HF, through a greater tendency
toward peripheral edema, dyspnea, or easy fatiga-
bility. The edema and dyspnea could be entirely
noncardiac (leading to misclassiﬁcation bias), or the
symptoms could simply present earlier in the disease
course (causing lead-time bias). In either case, me-
dian survival in obese patients would be longer than
that observed in leaner patients who are diagnosed
when the disease is further along.
As Khalid et al. (14) acknowledge, excluding
misclassiﬁcation or lead-time bias can be difﬁcult in
an epidemiological study, partly due to limited tools
for conﬁrming HF diagnosis or judging baseline
severity. Khalid et al. (14) based the HF diagnosis on
hospital discharge International Classiﬁcation of
Diseases-9th Revision (ICD-9) codes. The speciﬁcity
and positive predictive values of the ICD-9 HF deﬁ-
nition used in the study are only 23% and 77%,
respectively, as previously reported by the ARIC
investigators (15). The less speciﬁc the diagnosis of
HF in obese patients, the greater the likelihood of
observing artifactually-increased survival times.
The addition of the study by Khalid et al. (14) to the
body of evidence regarding the obesity paradox il-
lustrates the strengths and weaknesses of different
types of studies. Epidemiological studies such as
ARIC provide impressive longitudinal data and allow
BMI assessment unconfounded by the presence of
late-stage HF, but are vulnerable to biases that can be
difﬁcult to correct due to a lack of detailed clinical
information. Hospital-based studies feature such
comprehensive clinical and hemodynamic data; how-
ever, they are generally short in duration,making them
susceptible to confounding by a coexisting catabolic
state, reverse causality, or both (13).
What are the clinical and scientiﬁc implications of
understanding the obesity paradox? If low BMI is
merely a marker for late-stage HF, the clinical impli-
cations would seem limited. Alternatively, a causallink between low BMI and poorer prognosis (or,
conversely, between obesity and better survival)
would have intriguing implications, perhaps accoun-
ted for by biologically-plausible mechanisms. It has
been proposed that obese patients have greater
“metabolic reserve,” making them better able to
tolerate HF’s catabolic effects (16). Some experi-
mental data, for example, suggest that elevated li-
poproteins can be protective, binding endotoxins and
other inﬂammatory mediators that are elevated in
disorders such as HF (16,17).
Nonetheless, the evidence to support these mech-
anistic hypotheses is limited. To understand obesity’s
physiological consequences in HF, further work is
warranted in both experimental and human studies,
with the latter collecting more detailed metabolic and
physiological data in patients at various HF stages.
In the non-HF setting, evidence shows that a single
BMI measurement can mask considerable heteroge-
neity in cardiometabolic risk. Thus, patients who
are obese by BMI can still be “metabolically healthy”
and vice versa (18,19). Other factors, including fat
distribution, degree of systemic inﬂammation, ﬁtness
level, and insulin resistance, maintain comparable or
greater inﬂuences on metabolic health, and a number
of studies are examining these features in patients
with HF (9,11). Incorporating even more detailed
metabolic phenotyping in HF studies—using methods
such as metabolomics, novel imaging techniques, and
dietary interventions—could provide further insight.
Ultimately, a better mechanistic understanding of
what drives the obesity paradox should serve as the
basis for postulating whether an “optimal” BMI exists
for HF patients and whether interventions are war-
ranted to maintain or achieve this BMI.
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